Changes of macular sensitivity and morphology after pars plana vitrectomy for macular edema with central retinal vein occlusion: a case series

BMC Ophthalmology

Research Article

Katsunori Shimada¹  Tatsuya Mimura²  Hidetaka Noma³ 

[1] Department of Biostatistics, STATZ Institute Inc, Tokyo, Japan;Department of Ophthalmology, Medical Center East, Tokyo Women’s Medical University, Tokyo, Japan;Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women’s Medical University, 477-96, Owada-shinden, 276-8524, Yachiyo, Chiba, Japan;

关键词: Macular Edema;    Retinal Thickness;    Cystoid Macular Edema;    Central Retinal Vein Occlusion;    Triamcinolone Acetonide;   

DOI  :  10.1186/1471-2415-13-2

 received in 2012-08-28, accepted in 2013-01-30,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundIt is unclear how retinal ischemia influences the changes of visual acuity, macular sensitivity, macular thickness, and macular volume after the performance of pars plana vitrectomy (PPV) for macular edema in patients with central retinal vein occlusion (CRVO).MethodsTen patients (10 eyes) with CRVO and macular edema underwent PPV. Retinal ischemia was evaluated from the area of capillary nonperfusion on fluorescein angiography, and the patients were classified into ischemic or nonischemic groups. Microperimetry was performed with a Micro Perimeter 1. Macular thickness and volume were measured by optical coherence tomography.ResultsIn both groups, the mean macular thickness within the central 4°, 10°, and 20° fields decreased significantly from baseline to 3 and 6 months after PPV (all P < 0.05). In the ischemic group, the mean macular sensitivity within the central 4°, 10°, and 20° fields increased from baseline to 3 and 6 months after PPV, but no significant difference was observed.ConclusionsThese results suggest that PPV may be effective for improving macular thickness, volume, and sensitivity in patients with macular edema secondary to ischemic CRVO, although there was no significant difference.

【 授权许可】

CC BY   
© Noma et al.; licensee BioMed Central Ltd. 2013